Related Experiment Video
Updated: Mar 19, 2026
14:55
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
Published on: December 3, 2013
7.6K
Viral vectors as vaccine carriers
1Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, United States.
Current Opinion in Virology
|June 22, 2016
Summary
Viral vectors using adenoviruses show strong immune responses for infectious disease vaccines and are in clinical trials. Adeno-associated virus vectors are less immunogenic, except for a novel hybrid type needing more research.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Viral vectors are promising carriers for vaccines against infectious diseases.
- Adenoviruses and adeno-associated viruses are commonly studied vector types.
Purpose of the Study:
- To review the performance of adenovirus and adeno-associated virus vectors as vaccine carriers.
- To assess their immunogenicity and potential for clinical applications.
Main Methods:
- Review of existing literature on viral vector performance in vaccine development.
- Analysis of studies reporting B and T cell responses to transgene products.
- Evaluation of clinical trial data for adenovirus-based vaccine candidates.
Main Results:
- Replication-defective adenovirus vectors consistently induce potent transgene-specific B and T cell responses.
- Adenovirus vectors are increasingly being investigated in human clinical trials.
- Most adeno-associated virus vectors exhibit poor immunogenicity.
- A novel hybrid adeno-associated virus vector from rhesus macaques shows potent responses in mice.
Conclusions:
- Adenovirus vectors are effective vaccine carriers with proven immunogenicity and clinical trial progression.
- Further investigation of the novel rhesus macaque-derived adeno-associated virus hybrid vector is warranted due to its promising immunogenicity.
